Sinopharm unites (000028): Liangguang distribution leaders continue to unleash the operating potential of the national retail layout
Sinopharm is consistent (000028): Fee control effects are gradually showing optimism about improving profitability throughout the year
Sinopharm Unity (000028) Company In-depth Report: “Liangguang Distribution+National Retail” Dual Network Layout” Improving Quality and Efficiency “Accelerating Performance Growth”
Sinopharm is consistent (000028): Distribution business grows steadily and profitability continues to improve
Sinopharm is consistent (000028): The performance is in line with expectations, and the distribution sector has achieved steady growth
Sinopharm is consistent (000028): Distribution is growing steadily, and retail growth is slowing down under a high base
Sinopharm's consistent (000028) 2024Q1 performance review: steady distribution growth, retail growth decelerates under a high retail base
Sinopharm is consistent (000028): stable growth in the 1Q distribution sector and improved profitability
Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates decline
Sinopharm agrees (000028): Steady expansion of stores in 2023, net interest rate increase in retail business
Sinopharm is consistent (000028): The distribution sector is growing steadily, and the retail business is improving quality and efficiency
Sinopharm agrees (000028): 4Q distribution profit increased steadily and retail profit improved
Sinopharm agrees (000028): revenue from the distribution sector will pick up in 2023, and the net profit margin of the retail sector will increase year-on-year
Sinopharm agrees (000028): The base figure affects short-term performance and the growth rate is expected to pick up in 2024
Sinopharm Unify (000028): Increased profitability of retail business, expecting a month-on-month improvement in Q4 performance
Sinopharm Unify (000028): Short-term pressure in the 3rd quarter, net retail interest rates increased
Sinopharm Unify (000028): Performance is in line with expectations, retail sector profits continue to grow rapidly
Sinopharm is consistent (000028): Wholesale revenue is relatively stable, retail profit is improving
Sinopharm is consistent (000028): Liangguang Pharmaceutical's leading distribution retail pharmacy continues to release energy
Sinopharm Consistent (000028) 2023 Semi-Annual Results Report Review: Growth slows under base pressure and is expected to improve in the second half of the year
No Data